دورية أكاديمية
أعرض في EDS

The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.

التفاصيل البيبلوغرافية
العنوان: The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
المؤلفون: Artamonova OG; State Research Center for Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, Moscow, Russia. artamonova_olga@list.ru., Karamova AE; State Research Center for Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, Moscow, Russia., Nikonorov AA; State Research Center for Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, Moscow, Russia., Verbenko DA; State Research Center for Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, Moscow, Russia., Vasileva EL; State Research Center for Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, Moscow, Russia., Kubanov AA; State Research Center for Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, Moscow, Russia.
المصدر: Bulletin of experimental biology and medicine [Bull Exp Biol Med] 2021 May; Vol. 171 (2), pp. 208-211. Date of Electronic Publication: 2021 Jun 26.
نوع المنشور: Clinical Trial; Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 0372557 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-8221 (Electronic) Linking ISSN: 00074888 NLM ISO Abbreviation: Bull Exp Biol Med Subsets: MEDLINE
أسماء مطبوعة: Publication: New York : Springer
Original Publication: New York, Consultants Bureau.
مواضيع طبية MeSH: Cytokines/*metabolism , Janus Kinase Inhibitors/*pharmacology , Phosphodiesterase 4 Inhibitors/*pharmacology , Psoriasis/*drug therapy, Adult ; Cohort Studies ; Cytokines/blood ; Cytokines/drug effects ; Female ; Humans ; Janus Kinase Inhibitors/therapeutic use ; Male ; Middle Aged ; Phosphodiesterase 4 Inhibitors/therapeutic use ; Piperidines/pharmacology ; Piperidines/therapeutic use ; Psoriasis/blood ; Psoriasis/metabolism ; Psoriasis/pathology ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use ; Severity of Illness Index ; Skin/drug effects ; Skin/metabolism ; Thalidomide/analogs & derivatives ; Thalidomide/pharmacology ; Thalidomide/therapeutic use ; Treatment Outcome ; Young Adult
مستخلص: In patients with moderate-to-severe and severe psoriasis and high efficacy of therapy (PASI≥75) with signaling pathway inhibitors (apremilast, tofacitinib), cytokine spectra in the skin and blood plasma were studied using xMAP technology at baseline and on weeks 14 and 26 of treatment. Comparison of cytokine levels in psoriatic lesional skin and plasma samples of patients treated with apremilast or tofacitinib revealed statistical difference only for IFNγ level (р<0.05) at week 26.
References: Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R; OPT Compare Investigators. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomized non-inferiority trial. The Lancet. 2015;386:552-561. doi: https://doi.org/10.1016/S0140-6736(14)62113-9. (PMID: 10.1016/S0140-6736(14)62113-9)
Cataldi C, Mari NL, Lozovoy MAB, Martins LMM, Reiche EMV, Maes M, Dichi I, Simão ANC. Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors. Inflamm. Res. 2019;68(7):557-567. doi: https://doi.org/10.1007/s00011-019-01238-8. (PMID: 10.1007/s00011-019-01238-831062065)
Chiricozzi A, Romanelli P, Volpe E, Borsellino G, Romanelli M. Scanning the immunopathogenesis of psoriasis. Int. J. Mol. Sci. 2018;19(1):179. doi: https://doi.org/10.3390/ijms19010179. (PMID: 10.3390/ijms190101795796128)
Garcet S, Nograles K, Correa da Rosa J, Schafer PH, Krueger JG. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. J. Allergy Clin. Immunol. 2018;142(3):1010-1013.e6. doi: https://doi.org/10.1016/j.jaci.2018.05.039. (PMID: 10.1016/j.jaci.2018.05.03929936103)
Hall SA, Stucke D, Morrone B, Lebelt D, Zanella AJ. Simultaneous detection and quantification of six equine cytokines in plasma using a fluorescent microsphere immunoassay (FMIA). MethodsX. 2015;2:241-248. doi: https://doi.org/10.1016/j.mex.2015.04.002. (PMID: 10.1016/j.mex.2015.04.002261509944487921)
Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 2002;13(4-5):413-421. doi: https://doi.org/10.1016/s1359-6101(02)00026-6. (PMID: 10.1016/s1359-6101(02)00026-612220554)
Hwang YJ, Jung HJ, Kim MJ, Roh NK, Jung JW, Lee YW, Choe YB, Ahn KJ. Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis. Mediators Inflamm. 2014;2014:268257. doi: https://doi.org/10.1155/2014/268257. (PMID: 10.1155/2014/268257251971654150496)
Keating GM. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017;77(4):459-472. doi: https://doi.org/10.1007/s40265-017-0709-1. (PMID: 10.1007/s40265-017-0709-128213862)
Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review. Dermatol. Ther. (Heidelb). 2020;10(1):29-42. doi: https://doi.org/10.1007/s13555-019-00347-w. (PMID: 10.1007/s13555-019-00347-w)
Kubanov AA, Solomka VS, Karamova AE, Verbenko DA, Vasileva EL, Artamonova OG. The effect of apremilast therapy on skin cytokine levels in patients with psoriasis. Russ. Open Med. J. 2020;9(3):310-316. doi: https://doi.org/10.15275/rusomj.2020.0310. (PMID: 10.15275/rusomj.2020.0310)
Li H, Zuo J, Tang W. Phosphodiesterase-4 Inhibitors for the treatment of inflammatory diseases. Front. Pharmacol. 2018;9:1048. doi: https://doi.org/10.3389/fphar.2018.01048. (PMID: 10.3389/fphar.2018.01048303862316199465)
Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral J anus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br. J. Dermatol. 2015;173(4):949-961. doi: https://doi.org/10.1111/bjd.14018. (PMID: 10.1111/bjd.1401826149717)
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J. Am. Acad. Dermatol. 2015;73(1):37-49. doi: https://doi.org/10.1016/j.jaad.2015.03.049. (PMID: 10.1016/j.jaad.2015.03.04926089047)
Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG. Mechanisms underlying the clinical effects of apremilast for psoriasis. J. Drugs Dermatol;17(8):835-840.
Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, Ma H, Wei D, Sun S. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int. Immunopharmacol. 2020;80:106210. doi: https://doi.org/10.1016/j.intimp.2020.106210. (PMID: 10.1016/j.intimp.2020.10621031972425)
فهرسة مساهمة: Keywords: Janus kinase inhibitors; apremilast; phosphodiesterase-4 inhibitor; psoriasis; tofacitinib
المشرفين على المادة: 0 (Cytokines)
0 (Janus Kinase Inhibitors)
0 (Phosphodiesterase 4 Inhibitors)
0 (Piperidines)
0 (Pyrimidines)
4Z8R6ORS6L (Thalidomide)
87LA6FU830 (tofacitinib)
UP7QBP99PN (apremilast)
تواريخ الأحداث: Date Created: 20210626 Date Completed: 20220124 Latest Revision: 20220124
رمز التحديث: 20231215
DOI: 10.1007/s10517-021-05196-2
PMID: 34173094
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-8221
DOI:10.1007/s10517-021-05196-2